Phase 2 trials of sorafenib in RCC published following the TARGET trial.

Abbreviations: AE = adverse event; CI = confidence interval; CR = complete response; HFSR = hand foot skin reaction; NE = estimable; NR = not reported; OS = overall survival; PFS = progression-free survival; PR = partial response; SD = stable disease.a NR for 3 patients.b Tumor assessment was not possible in five patients and they were excluded from the efficacy analysis.c Treatment emergent AEs were reported for the total 202 patients, which included both patients randomized to the sorafenib and to the placebo arm after a 12 week run-in period of sorafenib treatment.d Interim analysis.e Median overall survival was not reached.f Unconfirmed.g All reported AEs were considered treatment related.h Grade ≥3.i Including 2 grade 5.Phase 2 trials of sorafenib in RCC published following the TARGET trial.